|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rustgi AK and El-Serag HB: Esophageal
carcinoma. N Engl J Med. 371:2499–2509. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stein HJ, Sendler A, Fink U and Siewert
JR: Multidisciplinary approach to esophageal and gastric cancer.
Surg Clin North Am. 80:659–686. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Copur S, Aiba K, Drake JC, Allegra CJ and
Chu E: Thymidylate synthase gene amplification in human colon
cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol.
49:1419–1426. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scherf U, Ross DT, Waltham M, Smith LH,
Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, et
al: A gene expression database for the molecular pharmacology of
cancer. Nat Genet. 24:236–244. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Denlinger CS, Ligibel JA, Are M, Baker KS,
Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Jones LW,
King A, et al: NCCN Guidelines Insights: Survivorship, Version
1.2016. J Natl Compr Canc Netw. 14:715–724. 2016.PubMed/NCBI
|
|
7
|
Inaba M, Mitsuhashi J, Sawada H, Miike N,
Naoe Y, Daimon A, Koizumi K, Tsujimoto H and Fukushima M: Reduced
activity of anabolizing enzymes in 5-fluorouracil-resistant human
stomach cancer cells. Jpn J Cancer Res. 87:212–220. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kikuchi O, Ohashi S, Nakai Y, Nakagawa S,
Matsuoka K, Kobunai T, Takechi T, Amanuma Y, Yoshioka M, Ida T, et
al: Novel 5-fluorouracil-resistant human esophageal squamous cell
carcinoma cells with dihydropyrimidine dehydrogenase
overexpression. Am J Cancer Res. 5:2431–2440. 2015.PubMed/NCBI
|
|
9
|
Look KY, Moore DH, Sutton GP, Prajda N,
Abonyi M and Weber G: Increased thymidine kinase and thymidylate
synthase activities in human epithelial ovarian carcinoma.
Anticancer Res. 17:2353–2356. 1997.PubMed/NCBI
|
|
10
|
Nakamura A, Nakajima G, Okuyama R,
Kuramochi H, Kondoh Y, Kanemura T, Takechi T, Yamamoto M and
Hayashi K: Enhancement of 5-fluorouracil-induced cytotoxicity by
leucovorin in 5-fluorouracil-resistant gastric cancer cells with
upregulated expression of thymidylate synthase. Gastric Cancer.
17:188–195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tang B, Zhang Y, Liang R, Gao Z, Sun D and
Wang L: RNAi-mediated EZH2 depletion decreases MDR1 expression and
sensitizes multidrug-resistant hepatocellular carcinoma cells to
chemotherapy. Oncol Rep. 29:1037–1042. 2013.PubMed/NCBI
|
|
12
|
Cai B, Miao Y and Liu Y, Xu X, Guan S, Wu
J and Liu Y: Nuclear multidrug-resistance related protein 1
contributes to multidrug-resistance of mucoepidermoid carcinoma
mainly via regulating multidrug-resistance protein 1: A human
mucoepidermoid carcinoma cells model and Spearman's rank
correlation analysis. PLoS One. 8:e696112013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wen J, Zheng B, Hu Y, Zhang X, Yang H, Luo
KJ, Zhang X, Li YF and Fu JH: Establishment and biological analysis
of the EC109/CDDP multidrug-resistant esophageal squamous cell
carcinoma cell line. Oncol Rep. 22:65–71. 2009.PubMed/NCBI
|
|
14
|
Yang AD, Fan F, Camp ER, van Buren G, Liu
W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic
oxaliplatin resistance induces epithelial-to-mesenchymal transition
in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Elliott BE, Hung WL, Boag AH and Tuck AB:
The role of hepatocyte growth factor (scatter factor) in
epithelial-mesenchymal transition and breast cancer. Can J Physiol
Pharmacol. 80:91–102. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Elshamy WM and Duhé RJ: Overview: Cellular
plasticity, cancer stem cells and metastasis. Cancer Lett. 341:2–8.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
He K, Xu T and Goldkorn A: Cancer cells
cyclically lose and regain drug-resistant highly tumorigenic
features characteristic of a cancer stem-like phenotype. Mol Cancer
Ther. 10:938–948. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lloyd RV, Hardin H, Montemayor-Garcia C,
Rotondo F, Syro LV, Horvath E and Kovacs K: Stem cells and cancer
stem-like cells in endocrine tissues. Endocr Pathol. 24:1–10. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu ZY, Tang JN, Xie HX, Du YA, Huang L, Yu
PF and Cheng XD: 5-Fluorouracil chemotherapy of gastric cancer
generates residual cells with properties of cancer stem cells. Int
J Biol Sci. 11:284–294. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen S, Song X, Chen Z, Li X, Li M, Liu H
and Li J: CD133 expression and the prognosis of colorectal cancer:
A systematic review and meta-analysis. PLoS One. 8:e563802013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Toden S, Okugawa Y, Jascur T, Wodarz D,
Komarova NL, Buhrmann C, Shakibaei M, Boland CR and Goel A:
Curcumin mediates chemosensitization to 5-fluorouracil through
miRNA-induced suppression of epithelial-to-mesenchymal transition
in chemoresistant colorectal cancer. Carcinogenesis. 36:355–367.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheng L, Luo S, Jin C, Ma H, Zhou H and
Jia L: FUT family mediates the multidrug resistance of human
hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell
Death Dis. 4:e9232013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Harada K, Ferdous T and Ueyama Y:
Establishment of 5-fluorouracil-resistant oral squamous cell
carcinoma cell lines with epithelial to mesenchymal transition
changes. Int J Oncol. 44:1302–1308. 2014.PubMed/NCBI
|
|
26
|
Tanaka T, Bai T and Toujima S:
Establishment and characterization of monoclonal
5-fluorouracil-resistant cell lines derived from human endometrial
adenocarcinoma. Int J Oncol. 37:731–736. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ohashi S, Kikuchi O, Tsurumaki M, Nakai Y,
Kasai H, Horimatsu T, Miyamoto S, Shimizu A, Chiba T and Muto M:
Preclinical validation of talaporfin sodium-mediated photodynamic
therapy for esophageal squamous cell carcinoma. PLoS One.
9:e1031262014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li B, Xu WW, Guan XY, Qin YR, Law S, Lee
NP, Chan KT, Tam PY, Li YY, Chan KW, et al: Competitive binding
between Id1 and E2F1 to Cdc20 regulates E2F1 degradation and
thymidylate synthase expression to promote esophageal cancer
chemoresistance. Clin Cancer Res. 22:1243–1255. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li B, Tsao SW, Chan KW, Ludwig DL,
Novosyadlyy R, Li YY, He QY and Cheung AL: Id1-induced IGF-II and
its autocrine/endocrine promotion of esophageal cancer progression
and chemoresistance - implications for IGF-II and IGF-IR-targeted
therapy. Clin Cancer Res. 20:2651–2662. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hummel R, Sie C, Watson DI, Wang T, Ansar
A, Michael MZ, Van der Hoek M, Haier J and Hussey DJ: MicroRNA
signatures in chemotherapy resistant esophageal cancer cell lines.
World J Gastroenterol. 20:14904–14912. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hummel R, Watson DI, Smith C, Kist J,
Michael MZ, Haier J and Hussey DJ: Mir-148a improves response to
chemotherapy in sensitive and resistant oesophageal adenocarcinoma
and squamous cell carcinoma cells. J Gastrointest Surg. 15:429–438.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shen LY, Wang H, Dong B, Yan WP, Lin Y,
Shi Q and Chen KN: Possible prediction of the response of
esophageal squamous cell carcinoma to neoadjuvant chemotherapy
based on gene expression profiling. Oncotarget. 7:4531–4541.
2016.PubMed/NCBI
|
|
33
|
Sasada S, Miyata Y, Tsutani Y, Tsuyama N,
Masujima T, Hihara J and Okada M: Metabolomic analysis of dynamic
response and drug resistance of gastric cancer cells to
5-fluorouracil. Oncol Rep. 29:925–931. 2013.PubMed/NCBI
|
|
34
|
Weljie AM, Newton J, Mercier P, Carlson E
and Slupsky CM: Targeted profiling: Quantitative analysis of 1H NMR
metabolomics data. Anal Chem. 78:4430–4442. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ouattara DA, Prot JM, Bunescu A, Dumas ME,
Elena-Herrmann B, Leclerc E and Brochot C: Metabolomics-on-a-chip
and metabolic flux analysis for label-free modeling of the internal
metabolism of HepG2/C3A cells. Mol Biosyst. 8:1908–1920. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ma Q, Jin B, Zhang Y, Shi Y, Zhang C, Luo
D, Wang P, Duan C, Song H, Li X, et al: Secreted recombinant human
IL-24 protein inhibits the proliferation of esophageal squamous
cell carcinoma Eca-109 cells in vitro and in vivo.
Oncol Rep. 35:2681–2690. 2016.PubMed/NCBI
|
|
37
|
Wang TH, Wan JY, Gong X, Li HZ and Cheng
Y: Tetrandrine enhances cytotoxicity of cisplatin in human
drug-resistant esophageal squamous carcinoma cells by inhibition of
multidrug resistance-associated protein 1. Oncol Rep. 28:1681–1686.
2012.PubMed/NCBI
|
|
38
|
Moghanibashi M, Jazii FR, Soheili ZS, Zare
M, Karkhane A, Parivar K and Mohamadynejad P: Proteomics of a new
esophageal cancer cell line established from Persian patient. Gene.
500:124–133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Baguley BC: Multidrug resistance in
cancer. Methods Mol Biol. 596:1–14. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang C, Guo LB, Ma JY, Li YM and Liu HM:
Establishment and characterization of a paclitaxel-resistant human
esophageal carcinoma cell line. Int J Oncol. 43:1607–1617.
2013.PubMed/NCBI
|
|
41
|
Dinicola S, Pasqualato A, Proietti S,
Masiello MG, Palombo A, Coluccia P, Canipari R, Catizone A, Ricci
G, Harrath AH, et al: Paradoxical E-cadherin increase in
5FU-resistant colon cancer is unaffected during
mesenchymal-epithelial reversion induced by γ-secretase inhibition.
Life Sci. 145:174–183. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yan XD, Li M, Yuan Y, Mao N and Pan LY:
Biological comparison of ovarian cancer resistant cell lines to
cisplatin and Taxol by two different administrations. Oncol Rep.
17:1163–1169. 2007.PubMed/NCBI
|
|
43
|
Longley DB and Johnston PG: Molecular
mechanisms of drug resistance. J Pathol. 205:275–292. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Denise C, Paoli P, Calvani M, Taddei ML,
Giannoni E, Kopetz S, Kazmi SM, Pia MM, Pettazzoni P, Sacco E, et
al: 5-Fluorouracil resistant colon cancer cells are addicted to
OXPHOS to survive and enhance stem-like traits. Oncotarget.
6:41706–41721. 2015.PubMed/NCBI
|
|
45
|
Kim NH, Kim SN, Oh JS, Lee S and Kim YK:
Anti-mitotic potential of
7-diethylamino-3(2′-benzoxazolyl)-coumarin in
5-fluorouracil-resistant human gastric cancer cell line
SNU620/5-FU. Biochem Biophys Res Commun. 418:616–621. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Uchibori K, Kasamatsu A, Sunaga M, Yokota
S, Sakurada T, Kobayashi E, Yoshikawa M, Uzawa K, Ueda S, Tanzawa
H, et al: Establishment and characterization of two
5-fluorouracil-resistant hepatocellular carcinoma cell lines. Int J
Oncol. 40:1005–1010. 2012.PubMed/NCBI
|
|
47
|
Langer R, Ott K, Feith M, Lordick F,
Specht K, Becker K and Hofler H: High pretherapeutic thymidylate
synthetase and MRP-1 protein levels are associated with nonresponse
to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients.
J Surg Oncol. 102:503–508. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Takebayashi Y, Akiyama S, Natsugoe S,
Hokita S, Niwa K, Kitazono M, Sumizawa T, Tani A, Furukawa T and
Aikou T: The expression of multidrug resistance protein in human
gastrointestinal tract carcinomas. Cancer. 82:661–666. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kim YK, Lee SS, Jeong SH, Ahn JS, Yang DH,
Lee JJ, Shin MG and Kim HJ: OCT-1, ABCB1, and
ABCG2 expression in imatinib-resistant chronic myeloid
leukemia treated with dasatinib or nilotinib. Chonnam Med J.
50:102–111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Benderra Z, Faussat AM, Sayada L, Perrot
JY, Tang R, Chaoui D, Morjani H, Marzac C, Marie JP and Legrand O:
MRP3, BCRP, and P-glycoprotein activities are prognostic factors in
adult acute myeloid leukemia. Clin Cancer Res. 11:7764–7772. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ke CC, Liu RS, Yang AH, Liu CS, Chi CW,
Tseng LM, Tsai YF, Ho JH, Lee CH and Lee OK: CD133-expressing
thyroid cancer cells are undifferentiated, radioresistant and
survive radioiodide therapy. Eur J Nucl Med Mol Imaging. 40:61–71.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Todaro M, Alea MP, Di Stefano AB,
Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G,
Medema JP, et al: Colon cancer stem cells dictate tumor growth and
resist cell death by production of interleukin-4. Cell Stem Cell.
1:389–402. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Najafzadeh N, Mazani M, Abbasi A,
Farassati F and Amani M: Low-dose all-trans retinoic acid enhances
cytotoxicity of cisplatin and 5-fluorouracil on CD44+
cancer stem cells. Biomed Pharmacother. 74:243–251. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Thomson S, Petti F, Sujka-Kwok I, Mercado
P, Bean J, Monaghan M, Seymour SL, Argast GM, Epstein DM and Haley
JD: A systems view of epithelial-mesenchymal transition signaling
states. Clin Exp Metastasis. 28:137–155. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Cioce M, Valerio M, Casadei L, Pulito C,
Sacconi A, Mori F, Biagioni F, Manetti C, Muti P, Strano S, et al:
Metformin-induced metabolic reprogramming of chemoresistant
ALDHbright breast cancer cells. Oncotarget. 5:4129–4143.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Makinoshima H, Takita M, Matsumoto S,
Yagishita A, Owada S, Esumi H and Tsuchihara K: Epidermal growth
factor receptor (EGFR) signaling regulates global metabolic
pathways in EGFR-mutated lung adenocarcinoma. J Biol Chem.
289:20813–20823. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Xie C, Jin J, Bao X, Zhan WH, Han TY, Gan
M, Zhang C and Wang J: Inhibition of mitochondrial glutaminase
activity reverses acquired erlotinib resistance in non-small cell
lung cancer. Oncotarget. 7:610–621. 2016.PubMed/NCBI
|
|
59
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Qian JQ, Sun P, Pan ZY and Fang ZZ:
Annonaceous acetogenins reverses drug resistance of human
hepatocellular carcinoma BEL-7402/5-FU and HepG2/ADM cell lines.
Int J Clin Exp Pathol. 8:11934–11944. 2015.PubMed/NCBI
|
|
61
|
Wang PP, Xu DJ, Huang C, Wang WP and Xu
WK: Astragaloside IV reduces the expression level of P-glycoprotein
in multidrug-resistant human hepatic cancer cell lines. Mol Med
Rep. 9:2131–2137. 2014.PubMed/NCBI
|
|
62
|
Li Q, Wang X, Shen A, Zhang Y, Chen Y,
Sferra TJ, Lin J and Peng J: Hedyotis diffusa Willd
overcomes 5-fluorouracil resistance in human colorectal cancer
HCT-8/5-FU cells by downregulating the expression of P-glycoprotein
and ATP-binding casette subfamily G member 2. Exp Ther Med.
10:1845–1850. 2015.PubMed/NCBI
|
